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ABSTRACT : The serum immunosuppressive (IS) levels were measured in the 73 
gastric cancer patients and analysed in terms of histoclinical factors of the progression 
of carcinoma. And also in vitro study was made to clarify the action of IS substrance 
on lymphocyte blastogenesis, NK and LAK cell activities. 
1) The serum IS levels in gastric cancer patients increased in accordance with progression 
of carcinomas. It is of great benefit to assess the advancing cancer progression and to 
know the prognosis. 
2) The serum IS levels inversely proportionated to lymphocyte blastogenesis, NK and LAK 
cell activities, in particular, showed close correlation with LAK cell activity. 
3) In vitro study clearly indicated that IS substance inhibited lymphocyte blastogenesis, 
as well as NK and LAK cell activities in accordance with IS dosis-dependent manner.
       INTRODUCTION 
 Recent study clarified a presence of immuno-
suppressive substance (IS) in the sera of tumor-
bearing hosts. 
 Fuji reported a presence of IS, glycoprotein, 
molecular weight 52,000, in the sera of gastric 
cancer patients, many investigators reported 
that IS could be not infrequently found in the 
sera of healthy humans but it increased in 
tumor-bearing hosts in proportion to immuno-
depressive states. 
 However, the mechanism to depress the im-
mune states was not entirely clarified to date. 
The purpose of this study is to clarify the 
correlation with histoclinical factors of gastric 
cancers and the influence on lymphoblasto-
genesis, and NK and LAK activities.
    MATERIAL AND METHOD 
 IS measurement was performed in 73 gastric 
cancer patients in contrast with the control in
whom included 20 benign diseases and 15 
healthy persons. Gastic cancer patients com-
prised of 42 men to 31 women and ranged. from 
33 to 75 years old (with an average of 57.9±9.9). 
On the other hand, benign disease patients were 
composed of 8 gastric ulcer, 12 cholecyto 
cholelithiases, with the ratio of 14 men to 6 
women, ranging from 40 to 72 years old with 
an average of 57.3±9.7 and healthy candidates 
were 10 men and 5 women, ranging from 29 to 
68 years old, averaged 46.3±10.7 years old. 
 IS measurement was performed according to 
single radical immunodiffusion method using 
anti-IS rabbit serum plates. 
 Blastogenesis was measured in accordance 
with the steps as described in Fig. 1. 
 The peripheral blood was collected with 
heparin using specific gravity centrifugation 
with the use of Ficoll-Hypaque solution. Adding 
10 g/ml PHA at 67CC, a 48 hour culture was 
achieved in addition to 0.1 Ci/well 3H-thym-
idin, washed and countered using by Liquid 
Scintillation Counter to get an intake of thym-
idine content as an expression of stimulation
        MONONUCLEAR CELLS 
 (Collected from human peripheral blood 2 x 106 
 using specific gravity centrifugation) 
 PHA 10/1g/ml 
 IS Substance 1000,ug/ml 
 RPML WITH 10%FCS 200,u1 
           48 hours incubated with                        5%CO2
, 37°C 
       Add 3H-Thymidine 0.1,uCi/well 
           24 hours incubated with                       5%CO2
, 37°C 
       RADIOACTIVITY ASSAY 
 WITH LIQULD SCINTILLATION COUNTER 
STIMULATION INDEX (S. I.) _ 
  cpm SAMPLE with PHA STIMULATION 
        cpm SAMPLE without PHA
Fig. 1. The shema of the assay for T cell prolif-
       erative response
       MONONUCLEAR CELLS 
   (Collected from human peripheral blood 
     using specific gravity centrifugation)
            1 hour incubated on                      pl
astic dish 
  Non-Adherent Cells 2 x 106/ml 
  IS Substance 1000pg/ml 
           20 hour incubation
      KILLER ACTIVITY ASSAY 
  EFFECTOR 2 x 105 
  (LYMPHOCYTES) 
  TARGET 
(51Cr-pretreated K 562) 5X103 
  RPMI WITH 10%FCS 200,ul 
            4 hour incubation 
RADIOACTIVITY ASSAT WITH y COUNTER 
KILLER ACTIVITY=%SPECIFIC LYSIS= M -S 
     E : EXPERIMENTAL RELEASE 
  M : MAXIMUM RELEASE WITH IN HCI 
      S : SPONTANEOUS RELEASE
Fig. 2. The schema of the assay for natural killer 
      activity
        MONONUCLEAR CELLS 
   (Collected from human peripheral blood 
     using specific gravity centrifugation)
            1 hour incubated on             j plastic dish
  Non-Adherent Cells 2 x 106/ml 
  IS Substance 1000,ug/ml 
  recombinant IL2 20 unit/ml 
           48 hour incubation 
      KILLER ACTIVITY ASSAY 
  EFFECTOR 2 x 105 
  (LYMPHOCYTES) 
  TARGET 3 
  (51Cr-pretreated RAJI) 5 X 10
  RPMI WITH 10%FCS 200,1 
            4 hour incubation 
RADIOACTIVITY ASSAT WITH 7 COUNTER 
KILLER ACTIVITY=%SPECIFIC LYSIS= M -S 
     E : EXPERIMENTAL RELEASE 
  M : MAXIMUM RELEASE WITH IN HCI 
      S : SPONTANEOUS RELEASE
Fig. 3. The shema od the assay for lymphokine 
      activated killer activity
index (SI) as shown in Fig. 1. For in vitro study, 
pure substance supplied from Kureha Co was 
prepared. NK activity was measured as summa-
rized in Fig. 1. 
 Human peripheral blood was collected with 
heparin and monocytes were provided using 
specific gravity centrifugation and cultured for 
1 hour in plastic dishes, non-adherent cells were 
collected in 10%. FCS+RPMI 1640 and prepared 
as 2 x 106 monocytes in suspension. K562 cells 
labelled with 51Cr were prepared for a target cell. 
Admixture of a ratio of 40: 1 of E : T was 
cultured for 4 hours and the radioactivity assay 
of the surpernatant was made by using r-
counter. Radioactivity was expressed as % 
specific lysis as shown in Fig. 2. 
 In vitro study 1000 g/ml purified IS was added 
to culture medium and incubated for 20 hours 
on various conditions. 
 LAK activity test was performed as summa-
rized in Fig. 3. Non-adherent cells in plastic
dishes as described in measuring NK activity 
incubated in 5% CO2 at 37°C for 48 hours in 
admixture with 20,u/ml recombinant interleukin 
2 (Ruk-2). Taget cell was labelled with 51Cr in 
admixture with a ratio of E : T of 40: 1. The 
action of 15 was tested by the addition of 
500g/ml pure IS in vitro study. The values of 
mean and standard errors were statistically 
analysed by student test.
          RESULTS 
 Serum IS concentrations averaged 661±230g/ 
ml in gastric cancer patients, In contrast, those 
in healthy subjects were 507±104g/ml and in 
benign diseases, 527±119g/m. With advances 
in disease stage, those were 541 ± 118g/ml in 
stage I, 618±267g/ml in stage II, 696±237g/ml 
in stage Ill and 898±413g/ml in stage N. Serum 
IS apparently increased in stage N (p<0.01). 
Positive rates in which the value of 700mg/ml 
were regarded as 100, were 5.9% in healthy 
subjects, 9.1% in benign deseases, 10.3% in stage 
I 25.0% in stage II 52.4% in stage III and 66.7% 
in stage N. IS level over 1000 g/ml included 
all 11 patients with advanced cancer, in 
particular 73% out of the 11 patients corre-
sponded to stage N gastric cancers (Fig. 4). 
 According to lymphnode involvement, the IS 
levels were 545±117 g/ml in no, 629±262 in nl 
876±438 g/ml in n2, 843±351 g/ml in n3 and 
positive rates were 12%, 30%, 69%, 58% 
respectively (Fig. 5). The IS levels were 
temporarily increased immediately after surgery 
and 3 weeks later, these fell down below the 
prior level in curative operation. On the other 
hand, it took about 3 months after surgery until
Fig. 4. The serum IS titer in patient with gastric 
      cancer according to clinacal stage
reached to previous level in patients with 
non-curative operation. In contrast, these re-
mained still high in patients with not resected 
surgery (Fig. 6). Fig. 7 showed close correla-
tion with serum IS level and CD4/CD8. The 
higher the serum IS levels, the lower CD4/CD8
Fig. 5. The serum IS titer in patient with gastric 
       cancer according to lymph node metastasis
Fig. 6. The changes of serum IS titer after 
      operation. Means of IS titer of resectable 
      cases (closed circle) and individual IS titer 
       of non-resectable case (open circle).
Fig. 7. The influence of serum IS titer on CD4/8 
      ratio of lymphocyte subpopullation
had shown. 
 In comparison with the serum IS levels and 
T cell proliferative responses there was inverse 
proportion indicating the coeficient index of 0.46 
as shown in Fig. 8. 
 On the other hand, NK and LAK activities 
were compared with serum IS levels. An 
increase in serum IS levels had led to re-
duced NK and LAK activities. The coeficient 
indices were -0.54 in NK activity and -0.62 in 
LAK activity as shown in Fig. 9 and 10. 
 Fig. 11 showed the effect of the addition of 
purified IS on T cell proliferative response. 
 In addition of 500 g/ml and 1000 g/ml purified 
IS, Fig. 11 showed that SI were depressed to 
87.0±30.3 and 70.0±28.1 g/ml, indicating a 
dosis-dependent relationship as compared with 
97.6 ± 32.9 without purified IS Fig. 12 showed 
that the addition of 1000 g/ml purified IS during 
a 20 hour incubation time of NK activity 
measurement allowed a slight depression of 51 ± 
13.4 as compared with 56.4±13.1 of no addition
of purified IS (p<0.05). 
 LAK activities showed 41.6±9.6 by adding 500 
g/ml IS and 28.7±7.8 by adding 1000g/ml, 
indicating the dosis-dependent inhibition of IS. 
As a result, the inhibitory rates were 83.3% by
Fig. 10. The influence of serum IS titer on 
      lymphokine activated killer activity
Fig. 8. The influence of serum IS titer on T cell 
      proliferative response
Fig. 11. The effect of IS substance on T cell 
       proliferative response. IS sibstance was
      added into medium during culture with 
     PHA.
Fig. 9. The influence of serum IS titer on natural 
      killer activity
Fig. 12. The effect of IS substance on natural killer 
      activity. IS substance (1,000 ug/ml) was added 
      into medium 20 hours before (Pretreat) and 
      during (at assay) cytotoxic assay.
Fig. 13. The effect of IS substance on lymphokine 
      activated killer activity. IS substance (500 
      or 1,000 ug/ml) was added into medium 
      before and during cytotoxic assay.
adding 5008/ml IS and 57.3% by adding 1000g/ 
ml IS.
         DISCUSSION 
 Many reports infer a depressed immune 
response in tumor bearing hosts, However, the 
mechanism is not yet obvious. It is widely 
accepted that one of them is associated with a 
presence of the immunosuppressive substance 
which was named immanosuppressive acidic 
protein (IAP) by Matsuda8) and IS by Fujii2). 
 There are reports that IAP and IS levels were 
reduced in the serum of a tumor-bearing host, 
indicating close relation to inhibited immune 
response. 
 A significant increase in serum IS as the 
tumor marker was reported in gastric cancer, 
colon cancer and carcinoma of the bile duct by 
Manami. Matsumoto5) clarified that IS levels 
indicated progression of the tumors in colon 
cancer. Noguchi4> also reported that an increase 
in the serum IS was remarkable in advanced 
and recurrent uterine cancers. 
 In this series, with advances in the disease 
stages the serum IS levels rose up. However 
positive rates were still lower even in early 
gastric cancer. It reflected that serum IS levels 
were inadequate for tumor markers to know a 
presence of gastric cancer in early stage. 
 It is substantiated that changes in serum IS 
levels closely refect the prognosis and it is of 
great benefit to know recurrence in early stage.
 To elucidate the immune state of tumor-
bearing hosts, delayed reaction of PPD used to 
be clinically available for clinical assessment. 
In this study it was certained that serum IS 
levels were in close proportion to CD4/CD8, NK 
and LAK activity and it is suggestion that serum 
IS levels should be an expression of the immune 
response of the tumor-bearing host. 
 It is well known that T cell proliferative re-
sponse is influenced by the action of inter-
leukin 2, macrophage and serum immunosup-
pressive substance, which is generated by 
peripheral lymphocytes, subsequently acts on 
peripheral lymphocytes and exhibits the 
immunosuppressive effects. It is elucidated in 
this study that lymphoblastogenesis stimulated 
by PHA was inhibited by the addition of purified 
IS in culture medium in accordance with 
dosis-dependent order. 
 The cytotoxic test by using NK and LAK' cells 
is now ongoing in addition of various kinds of 
cytokines. In this study it is clarified that 
cytotoxic effects of NK and LAK cells are 
affected by the time of adding IS substance prior 
to or immediatly before cytotoxic assay. 
Furthermore, the addition of IS substance just 
before cytotoxic assay does not demonstrate the 
inhibitory effect on cytotoxity with an aid of NK 
and LAK cells. From the standpoint of the 
result of this study, it is emphasized to assume 
that the inhibitory effect of IS substance on LAK 
cells is based on the inhibited response to LAK 
cells.
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